ClinicalTrials.gg
Active, not recruitingNCT07162883Updated Oct 22, 2026

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of QL2107 and Keytruda® in Carcinoma, Non-Small-Cell Lung, sponsored by Qilu Pharmaceutical Co., Ltd.. Active, not recruiting at 84 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Updated Oct 22, 2026Now Active, not recruitingFirst sites in 13 new countries+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Carcinoma, Non-Small-Cell Lung by Qilu Pharmaceutical Co., Ltd. — 5 open to participants now, 8 under way, 3 of them phase 3. Carcinoma, Non-Small-Cell Lung · Qilu Pharmaceutical Co., Ltd..

Planned enrollment
8th of 13
146 · median 176
Started
2025
the only one that year
Phase 3
4 of 14
1 open now
Registered
12th of 14
by date

Among the 14 studies in Carcinoma, Non-Small-Cell Lung by Qilu Pharmaceutical Co., Ltd., this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 4 in phase 3, and was the 12th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 14 studies in Carcinoma, Non-Small-Cell Lung by Qilu Pharmaceutical Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Carcinoma, Non-Small-Cell Lung by Qilu Pharmaceutical Co., Ltd., or all of them as a file.
02

Study summary

The primary purpose of this study is to demonstrate Pharmacokinetic similarity in exposure after the initial dose and at steady state of QL2107 compared with Keytruda.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • Respiratory Tract Neoplasms
  • Thoracic Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Lung Diseases
  • Respiratory Tract Diseases
  • Carcinoma, Bronchogenic
  • Bronchial Neoplasms
  • Neoplasm Metastasis
  • Neoplastic Processes
  • Pathologic Processes
  • Lung Neoplasms
  • Lymphatic Metastasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants (male or female) more than and equal to 18 years of age on the day of signing the ICF.
  • Disease status: Participants with completely resected, - or cytologically-confirmed (Stage II or IIIA) NSCLC
  • Treatment with platinum-based chemotherapy; • Chemotherapy must have begun within 12 weeks after the resection surgery. The last chemotherapy dose must have been completed at least 3 weeks and no more than 12 weeks before the participant is randomized.
  • No evidence of disease (NSCLC) for the post-surgery baseline assessment must be documented by full chest/abdomen/pelvis computed tomography (CT) and/or magnetic resonance imaging (MRI) and brain CT/MRI within 12 weeks prior to the randomization date.
  • performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Surgical-related adverse events (AEs) or chemotherapy-related toxicity not resolved to Grade 1, with the exception of Grade \<=2 alopecia, fatigue, neuropathy, and lack of appetite/nausea.
  • Participants who have received systemic (more than [>] 10 mg prednisone daily or equivalent) or other drugs (such as cyclophosphamide, azathioprine, methotrexate, thalidomide, or tumor necrosis factor alpha inhibitors) within 2 weeks prior to the first dose.
  • Participants with known epidermal growth factor receptor (EGFR)-sensitive mutations or anaplastic lymphoma kinase (ALK) gene translocations are not allowed.
  • Received prior therapy with an anticytotoxic T-lymphocyte antigen-4 mAb (example, ipilimumab); anti-programmed cell death 1 (), anti-programmed cell death ligand 1 (Programmed Death-Ligand 1), or anti-programmed cell death ligand 2 (PD-L2) agent; or agent directed to another stimulatory or co-inhibitory T cell receptor.
  • Participants with any active disease or history of autoimmune diseases including but not limited to autoimmune hepatitis, interstitial pneumonia, pulmonary fibrosis, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
146 participants (estimated)

Study arms

  • Experimental
    QL2107 200mg

    Participants will receive QL2107 200 milligrams (mg) intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21 days treatment cycle for up to 17 treatment cycles.

    Drug: QL2107

  • Active comparator
    Keytruda® 200 mg

    Participants will receive Keytruda® 200 mg IV infusion Q3W, on Day 1 of each 21- days treatment cycle for up to 17 treatment cycles.

    Drug: Keytruda®

Interventions

  • DrugQL2107

    IV infusion.

    Also known as: Pembrolizumab biosimilar candidate

  • IV infusion.

    Also known as: Pembrolizumab

06

What researchers measure

Primary outcomes

  1. AUCtau,sd of QL2107 and Keytruda

    Area under the concentration time curve for 1 dosing interval (tau = 21 days) after a single initial) dose (AUCtau,sd) of QL2107 and Keytruda® will be reported.

    Time frame: At Cycle 1 (cycle length = 21 days)]

  2. AUCtau,ss of QL2107 and Keytruda

    Area under the concentration time curve for 1 dosing interval (tau = 21 days) at steady state (AUCtau,ss) of QL2107 and Keytruda® will be reported.

    Time frame: At Cycle 7 (cycle length = 21 days)]

Secondary outcomes

  1. Cmax,sd of QL2107 and Keytruda

    Maximum (peak) serum concentration after a single dose (Cmax,sd) of QL2107 and Keytruda® will be reported.

    Time frame: At Cycle 1 (cycle length = 21 days)]

  2. Cmax,ss of QL2107 and Keytruda

    Maximum (peak) serum concentration at steady state (Cmax,ss) of QL2107 and Keytruda® will be reported.

    Time frame: At Cycle 7 (cycle length = 21 days)]

  3. Ctrough of QL2107 and Keytruda

    The trough serum concentration measured before the next dose is administered (Ctrough) of QL2107 and Keytruda® (predose samples) will be reported.

    Time frame: Up to Cycle 10 at Predose (cycle length = 21 days)

  4. Number of Participants With Antidrug Antibodies (ADAs) and Neutralizing Antibodies (NAbs)

    Time frame: Up to Week 52

  5. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to Week 52

07

Study locations

84 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 13 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Sep 2025 → Nov 2025 and completion May 2027 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2025
First posted
Sep 9, 2025
StartActual
Nov 21, 2025was Sep 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Nov 15, 2027was May 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 22, 2026
Sites
84 sites added — first sites in Bosnia and Herzegovina, China, Georgia, Greece, Hungary and 8 more
All 13 countries

Bosnia and Herzegovina, China, Georgia, Greece, Hungary, India, Poland, Romania, Spain, Thailand, Turkey (Türkiye), Ukraine, Vietnam

Show 84 added (25 China, 10 Turkey (Türkiye), 10 Ukraine, 9 Spain, 8 India, 5 Georgia, 4 Romania, 4 Thailand, 2 Greece, 2 Hungary, 2 Poland, 2 Vietnam, 1 Bosnia and Herzegovina)
  • Clinical Center University of Sarajevo, Oncology Department · Sarajevo, Bosnia and Herzegovina
  • The First Affiliated Hospital of Bengbu Medical University · Bengbu, China
  • Peking University People's Hospital · Beijing, China
  • Chinese People's Liberation Army Army Characteristic Medical Center) · Chongqing, China
  • Lanzhou University Second Hospital · Lanzhou, China
  • Hainan Cancer Hospital · Haikou, China
  • Henan Cancer Hospital · Zhengzhou, China
  • Henan Provincial Chest Hospital · Zhengzhou, China
  • Hunan Cancer Hospital · Changsha, China
  • Xiangya Hospital of Central South University · Changsha, China
  • Nanjing Drum Tower Hospital · Nanjing, China
  • First Affiliated Hospital of Gannan Medical University · Ganzhou, China
  • The First Hospital of China Medical University · Shenyang, China
  • Liaoning Cancer Hospital · Shenyang, China
  • Second Affiliated Hospital of the Air Force Medical University of the People's Liberation Army · Xi'an, China
  • Shandong Province Qianfo Mountain Hospital · Jinan, China
  • Affiliated Hospital of Jining Medical University · Jining, China
  • Weifang People's Hospital · Weifang, China
  • Shanghai Pulmonary Hospital · Shanghai, China
  • Shanxi Cancer Hospital · Taiyuan, China
  • Shanxi Provincial People's Hospital · Taiyuan, China
  • West China Hospital of Sichuan University · Chengdu, China
  • Tianjin Chest Hospital · Tianjin, China
  • Tianjin Medical University Cancer Institute & Hospital · Tianjin, China
  • Yunnan Cancer Hospital · Kunming, China
  • Taizhou Center Hospital (Taizhou University Affiliated Hospital) · Taizhou, China
  • Ltd "High Technology Hospital Medcenter" · Batumi, Georgia
  • Ltd "Israel-Georgian Medical Research Clinic Helsicore" · Tbilisi, Georgia
  • Ltd "Todua Clinic" · Tbilisi, Georgia
  • Ltd "Tbilisi State Medical University and Ingorokva High Technology University Clinic · Tbilisi, Georgia
  • …and 54 more on the registry record
Oct 22, 2026
Start date
Sep 1, 2025→Nov 21, 2025 (actual)
Oct 22, 2026
Study completion
May 31, 2027→Nov 15, 2027
Oct 22, 2026
Enrollment
122→146
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Not yet recruiting→Active, not recruiting
    84 sites added — first sites in Bosnia and Herzegovina, China, Georgia, Greece, Hungary and 8 more
    All 13 countries

    Bosnia and Herzegovina, China, Georgia, Greece, Hungary, India, Poland, Romania, Spain, Thailand, Turkey (Türkiye), Ukraine, Vietnam

    Show 84 added (25 China, 10 Turkey (Türkiye), 10 Ukraine, 9 Spain, 8 India, 5 Georgia, 4 Romania, 4 Thailand, 2 Greece, 2 Hungary, 2 Poland, 2 Vietnam, 1 Bosnia and Herzegovina)
    • Clinical Center University of Sarajevo, Oncology Department · Sarajevo, Bosnia and Herzegovina
    • The First Affiliated Hospital of Bengbu Medical University · Bengbu, China
    • Peking University People's Hospital · Beijing, China
    • Chinese People's Liberation Army Army Characteristic Medical Center) · Chongqing, China
    • Lanzhou University Second Hospital · Lanzhou, China
    • Hainan Cancer Hospital · Haikou, China
    • Henan Cancer Hospital · Zhengzhou, China
    • Henan Provincial Chest Hospital · Zhengzhou, China
    • Hunan Cancer Hospital · Changsha, China
    • Xiangya Hospital of Central South University · Changsha, China
    • Nanjing Drum Tower Hospital · Nanjing, China
    • First Affiliated Hospital of Gannan Medical University · Ganzhou, China
    • The First Hospital of China Medical University · Shenyang, China
    • Liaoning Cancer Hospital · Shenyang, China
    • Second Affiliated Hospital of the Air Force Medical University of the People's Liberation Army · Xi'an, China
    • Shandong Province Qianfo Mountain Hospital · Jinan, China
    • Affiliated Hospital of Jining Medical University · Jining, China
    • Weifang People's Hospital · Weifang, China
    • Shanghai Pulmonary Hospital · Shanghai, China
    • Shanxi Cancer Hospital · Taiyuan, China
    • Shanxi Provincial People's Hospital · Taiyuan, China
    • West China Hospital of Sichuan University · Chengdu, China
    • Tianjin Chest Hospital · Tianjin, China
    • Tianjin Medical University Cancer Institute & Hospital · Tianjin, China
    • Yunnan Cancer Hospital · Kunming, China
    • Taizhou Center Hospital (Taizhou University Affiliated Hospital) · Taizhou, China
    • Ltd "High Technology Hospital Medcenter" · Batumi, Georgia
    • Ltd "Israel-Georgian Medical Research Clinic Helsicore" · Tbilisi, Georgia
    • Ltd "Todua Clinic" · Tbilisi, Georgia
    • Ltd "Tbilisi State Medical University and Ingorokva High Technology University Clinic · Tbilisi, Georgia
    • …and 54 more on the registry record
    Start date Sep 1, 2025→Nov 21, 2025 (now actual)
    Study completion May 31, 2027→Nov 15, 2027
    Enrollment 122→146
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07162883
Responsible party
Sponsor
First posted
Sep 9, 2025
Start date
Nov 21, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Nov 15, 2027 (estimated)
Last update
Oct 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QL2107

Start the discussion